Please note that this position is based in Princeton, NJ. Acadia's hybrid model requires this role to work in our office three days per week on average.
Director, Incentive Compensation (Neuroscience & Rare Disease)
The Vision: Lead and transform Acadia’s incentive compensation strategy and execution across Neuroscience and Rare Disease for multiple field facing roles, ensuring flawless execution today while building a strategy-aligned, scalable model for tomorrow!
The Director of Incentive Compensation will serve as a subject matter expert in all areas of field incentive compensation plans, contests/SPIFFs, and award programs, with accountability across Neuroscience and Rare Disease multiple field teams. The person will lead strategic direction and continuous improvement of incentive compensation programs across therapeutic areas, applying advanced methodologies to complex business challenges with decisions that materially impact field performance, financial outcomes, and overall company success.
This role is responsible for leading the design, administration, and continuous improvement of incentive compensation programs that attract, retain, and motivate top field talent, while ensuring all programs are fiscally responsible, aligned with company and product goals/objectives, and administered in a consistent, accurate, timely, and compliant fashion.
As a player/coach leader, this role balances day-to-day execution (“run”) with advancing IC into a strategic, enterprise-aligned capability (“build”), strengthening alignment to brand strategic and tactical objectives and evolving IC into a true driver of field behavior and performance.
This role also provides proactive analyses of IC programs and practices, delivering insights and recommendations to senior leadership and governance committees.
Lead and develop IC team members (e.g., managers/analysts) as well as serve as a hands-on leader, stepping into design, modeling, and issue resolution as needed.
Primary Responsibilities
Lead and Administer Incentive Compensation
Design and Evolve IC Strategy
Govern IC Processes and Ensure Compliance
Reporting, Analytics, and Performance Transparency
Education / Experience / Skills
#LI-HYBRID #LI-CA1
In addition to a competitive base salary, this position is also eligible for discretionary bonus and equity awards based on factors such as individual and organizational performance. Actual amounts will vary depending on experience, performance, and location.
What we offer US-based Employees:
EEO Statement (US-based Employees): Studies have shown that women and people of color are less likely to apply for jobs unless they believe they meet every one of the qualifications in the exact way they are described in job postings. We are committed to building a diverse, equitable, inclusive, and innovative company, and we are looking for the BEST candidate for the job. That candidate may be one who comes from a less traditional background or may meet the qualifications in a different way. We strongly encourage you to apply, especially if the reason you are the best candidate isn’t exactly what we describe here.
It is the policy of Acadia to provide equal employment opportunities to all employees and employment applicants without regard to considerations of race, including related to hairstyle, color, religion or religious creed, sexual orientation, gender, gender identity, gender expression, gender transition, country of origin, ancestry, citizenship, age, physical or mental disability, genetic information, legally-protected medical condition or information, marital status, domestic partner status, family care status, military caregiver status, veteran or military status (including reserve status, National Guard status, and military service or obligation), status as a victim of domestic violence, sexual assault or stalking, enrollment in a public assistance program, or any basis protected under federal, state or local law.
As an equal opportunity employer, Acadia is committed to a diverse workforce. If you are a qualified individual with a disability or a disabled veteran, you have the right to request a reasonable accommodation. Furthermore, you may request additional support if you are unable or limited in your ability to use or access Acadia’s career website due to your disability, along with any accommodations throughout the interview process. To request or inquire about your reasonable accommodation, please complete our Reasonable Accommodation Request Form or contact us at talentacquisition@acadia-pharm.com or 858-261-2923
Please note that reasonable accommodations granted throughout the recruiting process are not guaranteed to be the same accommodations given if hired. A new request will need to be submitted for any ADA accommodations after starting employment.
California Applicants: Please see Additional Information for California Residents within our Privacy Policy.
Canadian Applicants: Please see Additional Information for Canadian Residents within our Privacy Policy.
Applicants in the European Economic Area, Switzerland, the United Kingdom, and Serbia: Please see Additional Information for Individuals in the European Economic Area, Switzerland, the United Kingdom, and Serbia within our Privacy Policy.
Notice to Search Firms/Third-Party Recruitment Agencies (Recruiters): The Talent Acquisition team manages the recruitment and employment process for Acadia Pharmaceuticals Inc. (“Acadia”). Acadia does not accept resumes from recruiters or search firms without an executed search agreement in place. Resumes sent to Acadia employees in the absence of an executed search agreement will not obligate Acadia in any way with respect to the future employment of those individuals or potential remuneration to any recruiter or search firm. Candidates should never be submitted directly to our hiring managers or employees.
At Acadia, our mission is to turn scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities around the world. Our commercial portfolio includes FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with early-stage programs that address other unmet patient needs.
